Clorox (NYSE:CLX) had its price objective reduced by Wells Fargo & Co from $157.00 to $153.00 in a research report sent to investors on Thursday, BenzingaRatingsTable reports. They currently have a market perform rating on the stock.
A number of other equities research analysts have also recently commented on the company. Bank of America reissued a neutral rating and issued a $154.00 price objective (down previously from $165.00) on shares of Clorox in a research note on Thursday. Citigroup reduced their price objective on Clorox from $171.00 to $160.00 and set a neutral rating for the company in a research note on Thursday. Deutsche Bank raised Clorox from a sell rating to a hold rating and set a $139.00 price objective for the company in a research note on Thursday. Zacks Investment Research raised Clorox from a sell rating to a hold rating in a research note on Tuesday, April 30th. Finally, JPMorgan Chase & Co. cut Clorox from a neutral rating to an underweight rating and reduced their price objective for the company from $159.00 to $139.00 in a research note on Monday, April 8th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $149.57.
Shares of CLX stock opened at $148.18 on Thursday. The company has a market capitalization of $18.99 billion, a price-to-earnings ratio of 23.67, a price-to-earnings-growth ratio of 3.72 and a beta of 0.31. The company has a quick ratio of 0.66, a current ratio of 1.10 and a debt-to-equity ratio of 2.93. Clorox has a fifty-two week low of $115.74 and a fifty-two week high of $167.70.
Clorox (NYSE:CLX) last issued its earnings results on Wednesday, May 1st. The company reported $1.44 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.47 by ($0.03). The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.57 billion. Clorox had a return on equity of 108.82% and a net margin of 12.68%. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.37 earnings per share. On average, research analysts anticipate that Clorox will post 6.29 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Wednesday, April 24th will be given a dividend of $0.96 per share. The ex-dividend date is Tuesday, April 23rd. This represents a $3.84 annualized dividend and a dividend yield of 2.59%. Clorox’s payout ratio is 61.34%.
In related news, SVP Matthew T. Laszlo sold 10,585 shares of Clorox stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $153.89, for a total transaction of $1,628,925.65. Following the transaction, the senior vice president now owns 17,994 shares of the company’s stock, valued at $2,769,096.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Andrew J. Mowery sold 5,340 shares of Clorox stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $156.44, for a total value of $835,389.60. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in CLX. Hancock Whitney Corp lifted its holdings in Clorox by 1.2% during the fourth quarter. Hancock Whitney Corp now owns 5,713 shares of the company’s stock worth $881,000 after acquiring an additional 67 shares during the period. Parsons Capital Management Inc. RI lifted its holdings in Clorox by 0.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 9,538 shares of the company’s stock worth $1,470,000 after acquiring an additional 70 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in Clorox by 9.7% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 849 shares of the company’s stock worth $136,000 after acquiring an additional 75 shares during the period. DAVENPORT & Co LLC lifted its holdings in Clorox by 1.2% during the fourth quarter. DAVENPORT & Co LLC now owns 6,611 shares of the company’s stock worth $1,019,000 after acquiring an additional 80 shares during the period. Finally, G&S Capital LLC lifted its holdings in Clorox by 46.4% during the fourth quarter. G&S Capital LLC now owns 262 shares of the company’s stock worth $40,000 after acquiring an additional 83 shares during the period. 76.98% of the stock is currently owned by institutional investors.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.